PAI
URGN icon

ProQuest Associates IV’s UroGen Pharma URGN Stock Holding History

ProQuest Associates IV’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$37.3M Hold
789,297
– – 70.39% 1
2018
Q2 		$39.3M Sell
789,297
-306,727
-28% -$17.9M 60.44% 1
2018
Q1 		$54.5M Hold
1,096,024
– – 62.61% 1
2017
Q4 		$40.8M Sell
1,096,024
-353,721
-24% -$12.6M 54.17% 1
2017
Q3 		$45.7M Sell
1,449,745
-1,584
-0.1% -$35K 45.77% 1
2017
Q2 		$26.2M Buy
+1,451,329
New +$25.2M 33.51% 1

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

ProQuest Associates IV's URGN Position: Q3 2018 in Review

ProQuest Associates IV held its UroGen Pharma (URGN) position steady in Q3 2018 at 789,297 shares worth $37.3M. The position accounts for 70.39% of the portfolio, ranked #1.

ProQuest Associates IV first reported a position in URGN in Q2 2017 and has held it in 6 quarters since. The position peaked at $54.5M in Q1 2018. 71 funds tracked by Wall St. Rank hold URGN as of Q3 2018.

  • ProQuest Associates IV held 789,297 shares of UroGen Pharma worth $37.3M as of Q3 2018.
  • ProQuest Associates IV left its UroGen Pharma share count unchanged in Q3 2018.
  • UroGen Pharma made up 70.39% of ProQuest Associates IV's portfolio in Q3 2018, its #1 holding.
  • ProQuest Associates IV first reported a position in UroGen Pharma in Q2 2017 and has held it in 6 quarters since.
  • ProQuest Associates IV's UroGen Pharma position peaked at $54.5M in Q1 2018.
  • 71 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2018.

Based on ProQuest Associates IV's 13F filing for Q3 2018, filed 14 Nov 2018.